Current Treatment Options in Oncology

, Volume 13, Issue 1, pp 11–23 | Cite as

Parathyroid Carcinoma: Update and Guidelines for Management

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Opinion statement

Parathyroid carcinoma is one of the rarest known malignancies that may occur sporadically or as a part of a genetic syndrome. It accounts for approximately 1% of patients with primary hyperparathyroidism. The majority (90%) of parathyroid cancer tumors are hormonally functional and hypersecrete parathyroid hormone (PTH). Thus, most patients exhibit strong symptomatology of hypercalcemia at presentation. Sometimes, it can be difficult to diagnose parathyroid cancer preoperatively due to clinical features shared with benign causes of hyperparathyroidism. Imaging techniques such as neck ultrasound and 99mTc sestamibi scan can help localize disease, but they are not useful in the assessment of malignancy potential. Fine needle aspiration (FNA) prior to initial operation is not recommended due to technical difficulty in differentiating benign and malignant disease on cytology specimens and the possible associated risk of tumor seeding from the needle track. Complete surgical resection with microscopically negative margins is the recommended treatment and offers the best chance of cure. Persistent or recurrent disease occurs in more than 50% of patients with parathyroid carcinoma. Surgical resection is also the primary mode of therapy for recurrence since it can offer significant palliation for the metabolic derangement caused by hyperparathyroidism and allows hypercalcemia to become more medically manageable. However, reoperation is rarely curative and eventual relapse is likely. Chemotherapy and external beam radiation treatments have been generally ineffective in the treatment of parathyroid carcinoma. Typically, these patients require repeated operations that predispose them to accumulated surgical risks with each intervention. In inoperable cases, few palliative treatment options exist, although treatment with calcimimetics can effectively control hypercalcemia in some patients. Most patients ultimately succumb to complications of hypercalcemia rather than from tumor burden or infiltration.

Keywords

Parathyroid cancer Diagnosis Treatment Evaluation Review 

Notes

Acknowledgements

1. Table 1: Phillip Ituarte, PhD (statistician, UCLA Endocrine Surgical Unit)

2. Figure 1: Photo taken by Matthew Denicola, MD (Pathology)

Disclosure

No potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Dudney WC, Bodenner D, Stack Jr BC. Parathyroid carcinoma. Otolaryngol Clin North Am. 2010;43(2):441–53. xi.PubMedCrossRefGoogle Scholar
  2. 2.
    Kebebew E, Arici C, Duh QY, et al. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136(8):878–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001;2(4):347–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):498–507.CrossRefGoogle Scholar
  6. 6.
    Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16(4):724–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Levin KE, Galante M, Clark OH. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery. 1987;101(6):649–60.PubMedGoogle Scholar
  8. 8.
    Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Kebebew E. Parathyroid carcinoma, a rare but important disorder for endocrinologists, primary care physicians, and endocrine surgeons. Thyroid. 2008;18(4):385–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metabol. 2010;24(3):491–502.CrossRefGoogle Scholar
  12. 12.
    Khan MW, Worcester EM, Straus 2nd FH, et al. Parathyroid carcinoma in secondary and tertiary hyperparathyroidism. J Am Coll Surg. 2004;199(2):312–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Fallah M, Kharazmi E, Sundquist J, et al. Nonendocrine cancers associated with benign and malignant parathyroid tumors. J Clin Endocrinol Metab. 2011;96(7):E1108–14.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metabol. 2011; in press.Google Scholar
  15. 15.
    Goldfarb M, O’Neal P, Shih JL, et al. Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism. Endocr Pract. 2009;15(5):463–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31(3):600–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilkins BJ, Lewis Jr JS. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol. 2009;3(2):140–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Gao WC, Ruan CP, Zhang JC, et al. Nonfunctional parathyroid carcinoma. J Cancer Res Clin Oncol. 2010;136(7):969–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Kebebew E, Clark OH. Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin N Am. 1998;7(4):721–48.PubMedGoogle Scholar
  20. 20.
    Wynne AG, van Heerden J, Carney JA, et al. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992;71(4):197–205.Google Scholar
  21. 21.
    Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26(8):716–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Wu B, Haigh PI, Hwang R, et al. Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(9):4324–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Sandelin K. Parathyroid carcinoma. In: Clark OH, Duh QY, Kebebew E, editors. Textbook of endocrine surgery. Philadelphia: Elsevier Saunders; 2005. p. 549–54.CrossRefGoogle Scholar
  24. 24.
    Patel CN, Salahudeen HM, Lansdown M, et al. Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin Radiol. 2010;65(4):278–87.PubMedCrossRefGoogle Scholar
  25. 25.
    Hara H, Igarashi A, Yano Y, et al. Ultrasonographic features of parathyroid carcinoma. Endocr J. 2001;48(2):213–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Sidhu PS, Talat N, Patel P, et al. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21(9):1865–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Harari A, Zarnegar R, Lee J, et al. Computed tomography can guide focused exploration in select patients with primary hyperparathyroidism and negative sestamibi scanning. Surgery. 2008;144(6):970–6. discussion 976-9.PubMedCrossRefGoogle Scholar
  28. 28.
    Kassahun WT, Jonas S. Focus on parathyroid carcinoma. Int J Surg. 2011;9(1):13–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Clark O. Parathyroid carcinoma. In: Doherty GM, Way LW, editors. Current surgical diagnosis and treatment. Michigan: McGraw-Hill Companies; 2006. p. 284–93.Google Scholar
  30. 30.
    Rodgers SE, Perrier ND. Parathyroid carcinoma. Curr Opin Oncol. 2006;18(1):16–22.PubMedCrossRefGoogle Scholar
  31. 31.
    Smith JF, Coombs RR. Histological diagnosis of carcinoma of the parathyroid gland. J Clin Pathol. 1984;37(12):1370–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Obara T, Fujimoto Y, Hirayama A, et al. Flow cytometric DNA analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma. Cancer. 1990;65(8):1789–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004;64(20):7405–11.PubMedCrossRefGoogle Scholar
  35. 35.
    Fernandez-Ranvier GG, Khanafshar E, Tacha D, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009;115(2):334–44.PubMedCrossRefGoogle Scholar
  36. 36.
    Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98(11):2378–84.PubMedCrossRefGoogle Scholar
  37. 37.
    Lefevre JH, Tresallet C, Leenhardt L, et al. Reoperative surgery for thyroid disease. Langenbecks Arch Surg. 2007;392(6):685–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Farrag TY, Agrawal N, Sheth S, et al. Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma. Head Neck. 2007;29(12):1069–74.PubMedCrossRefGoogle Scholar
  39. 39.
    Ariyan CE, Sosa JA. Assessment and management of patients with abnormal calcium. Crit Care Med. 2004;32(4 Suppl):S146–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Binstock ML, Mundy GR. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 1980;93(2):269–72.PubMedGoogle Scholar
  41. 41.
    Rodriguez A, Trujillo MJ, Herrero T, et al. Allergy to calcitonin. Allergy. 2001;56(8):801.PubMedCrossRefGoogle Scholar
  42. 42.
    Calandra DB, Chejfec G, Foy BK, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery. 1984;96(6):1132–7.PubMedGoogle Scholar
  43. 43.
    Bukowski RM, Sheeler L, Cunningham J, et al. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med. 1984;144(2):399–400.PubMedCrossRefGoogle Scholar
  44. 44.
    Chahinian AP, Holland JF, Nieburgs HE, et al. Metastatic nonfunctioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am J Med Sci. 1981;282(2):80–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Chow E, Tsang RW, Brierley JD, et al. Parathyroid carcinoma–the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1998;41(3):569–72.PubMedCrossRefGoogle Scholar
  46. 46.
    Warrell Jr RP, Issacs M, Alcock NW, et al. Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma. Ann Intern Med. 1987;107(5):683–6.PubMedGoogle Scholar
  47. 47.
    Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92(10):3803–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Betea D, Bradwell AR, Harvey TC, et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab. 2004;89(7):3413–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet. 1999;353(9150):370–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Montenegro FL, Chammas MC, Juliano AG, et al. Ethanol injection under ultrasound guidance to palliate unresectable parathyroid carcinoma. Arq Bras Endocrinol Metabol. 2008;52(4):707–11.PubMedCrossRefGoogle Scholar
  51. 51.
    Stratigis S, Stylianou K, Mamalaki E, et al. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;69(4):542–8.CrossRefGoogle Scholar
  52. 52.
    Mauz PS, Stiegler M, Holderried M, et al. Complications of ultrasound guided percutaneous ethanol injection therapy of the thyroid and parathyroid glands. Ultraschall Med. 2005;26(2):142–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Tochio M, Takaki H, Yamakado K, et al. A case report of 20 lung radiofrequency ablation sessions for 50 lung metastases from parathyroid carcinoma causing hyperparathyroidism. Cardiovasc Intervent Radiol. 2010;33(3):657–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Section of Endocrine Surgery, Department of SurgeryUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations